WO2022107673A1 - Boisson contenant du placenta et du fer - Google Patents
Boisson contenant du placenta et du fer Download PDFInfo
- Publication number
- WO2022107673A1 WO2022107673A1 PCT/JP2021/041452 JP2021041452W WO2022107673A1 WO 2022107673 A1 WO2022107673 A1 WO 2022107673A1 JP 2021041452 W JP2021041452 W JP 2021041452W WO 2022107673 A1 WO2022107673 A1 WO 2022107673A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iron
- beverage
- placenta extract
- placenta
- collagen peptide
- Prior art date
Links
- 210000002826 placenta Anatomy 0.000 title claims abstract description 74
- 235000013361 beverage Nutrition 0.000 title claims abstract description 73
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims description 48
- 229910052742 iron Inorganic materials 0.000 title claims description 24
- 239000000284 extract Substances 0.000 claims abstract description 62
- 241001465754 Metazoa Species 0.000 claims abstract description 41
- 150000002506 iron compounds Chemical class 0.000 claims abstract description 35
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 37
- 102000008186 Collagen Human genes 0.000 claims description 34
- 108010035532 Collagen Proteins 0.000 claims description 34
- 229920001436 collagen Polymers 0.000 claims description 33
- 238000001556 precipitation Methods 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- PLKYGPRDCKGEJH-UHFFFAOYSA-N azane;2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound N.[Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O PLKYGPRDCKGEJH-UHFFFAOYSA-N 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 8
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 claims description 6
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 4
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 claims description 3
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims description 3
- 239000011706 ferric diphosphate Substances 0.000 claims description 3
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 3
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 3
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 3
- 239000011773 ferrous fumarate Substances 0.000 claims description 3
- 235000002332 ferrous fumarate Nutrition 0.000 claims description 3
- 229960000225 ferrous fumarate Drugs 0.000 claims description 3
- 239000004222 ferrous gluconate Substances 0.000 claims description 3
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 3
- 229960001645 ferrous gluconate Drugs 0.000 claims description 3
- 239000011790 ferrous sulphate Substances 0.000 claims description 3
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- ATEAWHILRRXHPW-UHFFFAOYSA-J iron(2+);phosphonato phosphate Chemical compound [Fe+2].[Fe+2].[O-]P([O-])(=O)OP([O-])([O-])=O ATEAWHILRRXHPW-UHFFFAOYSA-J 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 3
- ZCFFYALKHPIRKJ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(=C(C)C(=CC=3C(C)=C(CCC(O)=O)C(N=3)=C3)N2)C=C)=C(C)C(C=C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 ZCFFYALKHPIRKJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 abstract description 13
- 230000000052 comparative effect Effects 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000008213 purified water Substances 0.000 description 20
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 241000282887 Suidae Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 5
- 229960004106 citric acid Drugs 0.000 description 5
- 235000019688 fish Nutrition 0.000 description 5
- 235000019515 salmon Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 4
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- 229960002303 citric acid monohydrate Drugs 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000019534 high fructose corn syrup Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000004313 iron ammonium citrate Substances 0.000 description 2
- 235000000011 iron ammonium citrate Nutrition 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 210000004993 mammalian placenta Anatomy 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229910000462 iron(III) oxide hydroxide Inorganic materials 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- -1 royal jelly Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Definitions
- the present invention can be used in the fields of pharmaceuticals, quasi-drugs, foods, etc. with respect to beverages containing animal placenta extract.
- Animal placenta extract is an extract extracted from the placenta of mammals such as pigs, cows, horses, humans or sheep. Mammalian placenta tissue is rich in amino acids, active peptides, vitamins, minerals, sugars, enzymes, nucleic acids, etc., which are essential nutrients for fetal growth, and is an extract extracted from the mammalian placenta. Is called placenta extract (Patent Document 1). Since the animal placenta extract has a peculiar taste and odor, a masking technique when ingested as a beverage has been reported (Patent Document 2).
- An object of the present invention is to provide a beverage having a low carbohydrate content, which suppresses the formation of precipitates derived from animal placenta extract.
- the present inventors have unexpectedly found that the formation of a precipitate can be suppressed by blending an iron compound, and have completed the present invention. Further, they have found that the effect of suppressing precipitation formation is further enhanced by blending an iron compound and a collagen peptide, and have completed the present invention.
- the aspects of the present invention obtained from such findings are as follows.
- the iron compound is ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, sodium ferrous citrate, ferrous gluconate, iron lactate, ferrous pyrophosphate, pyrrolin.
- the beverage according to (1) to (3) which is at least one selected from the group consisting of ferric acid acid, ferrous sulfate and iron hem.
- the beverage according to (2) to (6), wherein the content of collagen peptide is 0.02 to 20 w / v%.
- the beverage according to (1) to (7) which has a pH of 2.5 to 4.5.
- a method for suppressing precipitation formation which comprises blending an iron compound in a beverage containing animal placenta extract.
- a method for suppressing precipitation formation which comprises an iron compound and a collagen peptide in a beverage containing animal placenta extract. Is.
- the animal placenta which is the raw material of the animal placenta extract used in the present invention, is not particularly limited, and is, for example, an edible placenta obtained as a postpartum at the time of full-term delivery of a healthy animal properly bred on a farm, such as the uterus. It is a marine placenta-like substance that does not contain external organs or is contained in the placenta of fish and the like.
- the origin thereof is not particularly limited, and examples thereof include humans, cows, pigs, horses, sheep, and salmon, but pigs, horses, and salmon are preferable, and pigs are more preferable.
- the form of the animal placenta extract is not particularly limited, and is, for example, a liquid or paste obtained through an extraction step after being decomposed by a method such as enzymatic decomposition or hydrochloric acid decomposition, and may be freeze-dried or spray-dried. , It may be in the form of a powder from which water has been removed.
- animal placenta extract of the present invention a commercially available product may be used, for example, "Pig Placenta Extract AL-20” (manufactured by Sankyo Biochemicals Co., Ltd.) and "Horse Placenta Extract AL-20” (Sankyo Bio Co., Ltd.).
- the content of the animal placenta extract of the present invention is preferably 0.001 to 4 w / v%, more preferably 0.01 to 2 w / v%, and further preferably 0.02 to 2 w / v% in the beverage of the present invention.
- the placenta-equivalent amount is preferably 0.025 to 100 w / v%, more preferably 0.25 to 50 w / v%.
- the "placenta-equivalent amount" is the amount of placenta required to obtain the placenta extract.
- the content of the placenta extract is preferably 0.005 to 20000 parts by mass, more preferably 0.025 to 2000 parts by mass with respect to 1 part by mass of iron in terms of iron compound (iron equivalent) described later. It is preferable, 0.5 to 1000 parts by mass is more preferable, and 10 to 200 parts by mass is particularly preferable. In terms of placenta, 0.125 to 500,000 parts by mass is preferable, 0.625 to 50,000 parts by mass is more preferable, and 12.5 to 25,000 parts by mass is most preferable with respect to 1 part by mass of the iron compound (iron equivalent).
- the "iron compound” may be either a divalent iron compound or a trivalent iron compound, for example, ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, or ferrous citrate.
- a divalent iron compound for example, ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, or ferrous citrate.
- examples thereof include sodium monoferric acid, ferrous gluconate, iron lactate, ferrous pyrophosphate, ferric pyrophosphate, ferrous sulfate and hem iron.
- trivalent iron compounds such as ferric chloride, iron citrate, ammonium iron citrate and ferric pyrophosphate are preferable.
- the content of the iron compound in the beverage of the present invention is preferably 0.0002 to 0.2 w / v%, more preferably 0.001 to 0.1 w / v%, and 0.002 to 0.04 w in terms of iron. / V% is more preferred.
- the iron compound is preferably 0.001 to 2.0 w / v%, more preferably 0.005 to 1.2 w / v%, and even more preferably 0.01 to 0.5 w / v%.
- the iron compound content in the beverage of the present invention preferably has an upper limit of 0.2 w / v%, more preferably 0.1 w / v%, and 0.04 w / v in terms of iron. v% is most preferable.
- the content of the iron compound in the beverage of the present invention is preferably 1 mg to 20 mg in terms of iron per oral intake.
- the single oral intake is the amount by which the beverage of the present invention is orally ingested at one time, for example, 30 to 200 ml, typically 30 ml, 50 ml, 100 ml, 150 ml, 200 ml.
- the amount is, for example, 15 to 200 g, typically 15 g, 30 g, 50 g, 100 g, 150 g, 150 g, 200 g.
- the form of the oral liquid container or the beverage container is not particularly limited.
- the capacity of the container is not particularly limited, but can be, for example, 30 ml to 200 ml (typically 50 ml, 100 ml, 150 ml, or 200 ml).
- the beverage of the present invention has a carbohydrate content of 0 to 40 w / v%, more preferably 0 to 20 w / v%, still more preferably 0 to 15% w / v%, and particularly preferably 0 to 0 to. It is 10 w / v%.
- Carbohydrates include sugar, high fructose corn syrup, fructose, fructose-fructose syrup, fructose-fructose syrup, honey, starch syrup, powdered starch syrup, maltodextrin, sorbitol, martitol, reduced starch syrup, maltose, trehalose, brown sugar, etc. Examples thereof include organic acids such as citric acid and fructose.
- the calorie of the beverage of the present invention is preferably 0 to 150 kcal / 100 ml, more preferably 0 to 100 kcal / 100 ml, and even more preferably 0 to 70 kcal / 100 ml.
- the origin of the "collagen peptide” is not particularly limited and may be synthetic, and the skin, bone, ligament, tendon, and cartilage produced as a by-product when processing livestock such as cows and pigs and fish It may be a collagen peptide produced by extracting from the above, but a collagen peptide derived from pig and fish is preferable.
- a collagen peptide obtained by decomposing collagen protein by enzyme, chemical treatment or the like is preferable.
- the average molecular weight of the collagen peptide is not particularly limited, but is preferably 500 to 50,000, and more preferably 1,000 to 25,000.
- collagen peptide of the present invention a commercially available product may be used, for example, "Nippi Peptide PS-1” (registered trademark, manufactured by Nippi Co., Ltd.), “Nippi Peptide PRA-P” (registered trademark, manufactured by Nippi Co., Ltd.).
- the content of collagen peptide is preferably 0.02 to 20 w / v%, more preferably 0.1 to 15 w / v%, still more preferably 0.2 to 15 w / v% in the beverage of the present invention. ..
- the content of collagen peptide is preferably 0.1 to 100,000 parts by mass, more preferably 0.5 to 10,000 parts by mass, based on 1 part by mass of iron in terms of iron compound (iron equivalent). It is more preferably 7500 parts by mass, and particularly preferably 20 to 7500 parts by mass. Further, 0.005 to 20000 parts by mass is preferable, 0.01 to 1000 parts by mass is more preferable, 0.1 to 750 parts by mass is further preferable, and 0.5 to 150 parts by mass is preferable with respect to 1 part by mass of placenta extract. Especially preferable.
- placenta extract When the placenta extract is converted into a placenta, 0.0002 to 800 parts by mass is preferable, 0.002 to 40 parts by mass is more preferable, 0.004 to 30 parts by mass is more preferable, and 0 is 0 parts by mass of the placenta. .02 to 6 parts by mass is particularly preferable.
- the present invention can suppress the formation of a precipitate derived from animal placenta extract by blending an iron compound. Further, when collagen peptide is further added, the effect of suppressing the formation of the precipitate derived from the animal placenta extract is enhanced.
- the animal placenta is not particularly limited, but when the formation of the precipitate is suppressed only by the iron compound, the pig-derived animal placenta is particularly preferable.
- the beverage in the present invention is not particularly limited as long as it is a liquid that can be orally ingested, and is a drug, a non-medicinal product, or a food (not only general foods, but also nutritionally functional foods, foods for specified health uses, and foods with functional claims). Also included).
- Examples of pharmaceuticals and quasi-drugs include internal liquids and drinks. Examples of foods include soft drinks, carbonated drinks, sports / functional drinks, non-alcoholic drinks, dairy drinks, tea drinks, coffee drinks, fruit / vegetable drinks, jelly drinks and the like. More preferably, it is an internal liquid or drink for pharmaceuticals and quasi-drugs, and various beverages such as nutritional functional foods and foods for specified health use, carbonated beverages and jelly beverages for foods.
- the pH of the beverage of the present invention is not particularly limited, but is preferably 2.5 to 4.5, more preferably 3.0 to 4.0, from the viewpoint of good mouthfeel.
- a pH adjuster such as an organic acid can be added as needed.
- the beverage of the present invention can be produced by a conventional method, and the method is not particularly limited. Usually, it is obtained by weighing each component, dissolving and stirring with an appropriate amount of purified water, adjusting the pH, further adding purified water to adjust the volume, and performing filtration and sterilization treatment as necessary.
- the beverage of the present invention as other components, vitamins, minerals, amino acids and salts thereof, crude drugs, crude drug extracts, caffeine, royal jelly, dextrin and the like are appropriately added as long as the effects of the present invention are not impaired. Can be blended. Further, if necessary, additives such as antioxidants, colorants, flavors, flavoring agents, preservatives, sweeteners, and acidulants can be appropriately blended as long as the effects of the present invention are not impaired.
- Beverages with the formulations listed in Table 1 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water and the volume was adjusted so as to contain 0.2 to 0.4 w / v% as iron to obtain an iron solution. To the acidulant solution, add an iron solution or iron compound and pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) as necessary so that the formulation shown in the table is obtained, and the total amount is 90v /.
- P-placenta extract manufactured by Nippon Ham Co., Ltd. pig-derived animal placenta extract manufactured by Nippon Ham Co., Ltd.
- Examples 1-1 to 4-1 Purified water was added so as to be about v%, and the mixture was sufficiently stirred. After sufficient stirring, the pH was adjusted with hydrochloric acid or sodium hydroxide, and purified water was added to make the total amount to obtain a beverage (Examples 1-1 to 4-1). These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. Beverages to which ammonium ferric citrate was not added (Comparative Examples 1 to 4) were used as controls. The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
- Example 1-1 for Comparative Example 1, Examples 2-1 to 2-3 for Comparative Example 2, and Examples 3-1 to 3-5 for Comparative Example 3-1.
- Example 4-1 precipitation formation was suppressed by blending the iron compound.
- the beverages of the formulations shown in Tables 3 and 4 below were prepared according to the following methods. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount with purified water to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water, and the volume was adjusted so as to contain 0.2 to 0.4 w / v% as iron to obtain an iron solution. If necessary, add an iron solution or an iron compound to the acidulant solution so as to be as shown in the table, and add pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) and collagen peptide.
- P-placenta extract manufactured by Nippon Ham Co., Ltd.
- Example 42 Collagen peptide derived from pigs (molecular weight about 5000) is Korapep JB (registered trademark, manufactured by Nitta Gelatin Co., Ltd.), and collagen peptide derived from pigs (molecular weight about 4000-12000) is Nippi Peptide PRA-P (registered trademark, manufactured by Nitta Gelatin Co., Ltd.).
- Nippi Peptide FCP-EX (registered trademark, manufactured by Nippi Co., Ltd.) was used as the collagen peptide derived from fish (manufactured by Nippi) and fish-derived collagen peptide (molecular weight of about 4000). These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. Beverages to which ammonium iron citrate and collagen peptide were not added (Comparative Examples 1 to 4) were used as controls. The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
- Beverages with the formulations listed in Table 5 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted with purified water having a total amount of about 60 v / v% to obtain an acidulant solution. Next, sodium ferrous citrate, pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) and collagen peptide are added in order, and purified water is added so that the total amount is about 90 v / v%. , Stirred well.
- citric acid citric acid monohydrate
- sodium benzoate sodium benzoate
- Example 3-14 a beverage
- These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes.
- the beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
- a beverage to which sodium ferrous citrate and collagen peptide were not added (Comparative Example 3-1) was used as a control.
- Beverages with the formulations listed in Table 6 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount with purified water to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water, and the volume was adjusted so as to contain 0.4 w / v% as iron to obtain an iron solution. Add an iron solution to the acidulant solution according to the formulation shown in the table, and add salmon-derived placenta extract (Japan Barrier Free Marine Placenta (MP)) or horse-derived placenta extract (Dard Co., Ltd. horse).
- MP Job Barrier Free Marine Placenta
- the melon placenta-derived plant placenta extract was blended to obtain a beverage by the same method as the preparation in Table 1 or Table 3 (Comparative Examples 7-1 to 8-). 2).
- These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes.
- the beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2. Beverages to which ammonium iron citrate and collagen peptide were not added (Comparative Examples 7-1 and 8-1) were used as controls.
Abstract
Le problème à résoudre par la présente invention est de fournir une boisson dont la production de précipités dérivés d'un extrait de placenta animal est réduite et dont la teneur en glucides est réduite. La solution selon l'invention porte sur une boisson étant caractérisée en ce qu'elle comprend un extrait de placenta animal et un composé de fer et ayant une teneur en hydrates de carbone de 40 % p/v ou moins.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021576325A JP7112040B1 (ja) | 2020-11-19 | 2021-11-11 | プラセンタと鉄を含む飲料 |
JP2022008167A JP2022081472A (ja) | 2020-11-19 | 2022-01-21 | プラセンタと鉄を含む飲料 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020192121 | 2020-11-19 | ||
JP2020-192121 | 2020-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022107673A1 true WO2022107673A1 (fr) | 2022-05-27 |
Family
ID=81708827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/041452 WO2022107673A1 (fr) | 2020-11-19 | 2021-11-11 | Boisson contenant du placenta et du fer |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP7112040B1 (fr) |
WO (1) | WO2022107673A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11221047A (ja) * | 1997-10-29 | 1999-08-17 | Masakazu Matsushima | プラセンタエキス含有液剤 |
WO2005107734A1 (fr) * | 2004-05-06 | 2005-11-17 | Taiyokagaku Co., Ltd. | Composition accélérant le métabolisme de l'alcool et aliment ou boisson contenant la composition |
JP4715078B2 (ja) * | 2003-04-16 | 2011-07-06 | 大正製薬株式会社 | 鉄化合物配合内服用液体組成物 |
-
2021
- 2021-11-11 JP JP2021576325A patent/JP7112040B1/ja active Active
- 2021-11-11 WO PCT/JP2021/041452 patent/WO2022107673A1/fr active Application Filing
-
2022
- 2022-01-21 JP JP2022008167A patent/JP2022081472A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11221047A (ja) * | 1997-10-29 | 1999-08-17 | Masakazu Matsushima | プラセンタエキス含有液剤 |
JP4715078B2 (ja) * | 2003-04-16 | 2011-07-06 | 大正製薬株式会社 | 鉄化合物配合内服用液体組成物 |
WO2005107734A1 (fr) * | 2004-05-06 | 2005-11-17 | Taiyokagaku Co., Ltd. | Composition accélérant le métabolisme de l'alcool et aliment ou boisson contenant la composition |
Non-Patent Citations (1)
Title |
---|
Frozen Smoothie. Record number (ID#) 2983877. Mintel GNPD. 2015, [online], [retrieved on 21 December 2021], Retrieved from the Internet: <URL: https://www.gnpd.com/sinatra/recordpage/2983877/> in particular, Product name, raw material name and nutritional facts label in the product photo * |
Also Published As
Publication number | Publication date |
---|---|
JP2022081472A (ja) | 2022-05-31 |
JPWO2022107673A1 (fr) | 2022-05-27 |
JP7112040B1 (ja) | 2022-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201204268A (en) | Substantially clear nutritional liquids comprising calcium HMB and soluble protein | |
JPWO2005084461A1 (ja) | ミネラル含有酸性たん白飲食品 | |
WO1994009650A1 (fr) | Promoteur de croissance de bifidus | |
JP5465834B2 (ja) | 肝機能保護剤 | |
CN103976023A (zh) | 一种黄秋葵酸乳饮料及其制备方法 | |
JP2006180812A (ja) | ゼリー飲料 | |
CN104768384B (zh) | 浓缩类型的乳性酸性饮料及其制造方法 | |
JP7082237B1 (ja) | コラーゲンと鉄を含む飲料 | |
JPH07222571A (ja) | 運動選手用飲食品 | |
JP7112040B1 (ja) | プラセンタと鉄を含む飲料 | |
JP2007215498A (ja) | 妊婦用飲料 | |
JP6841371B1 (ja) | 鉄化合物およびコラーゲン含有組成物 | |
CN107495050A (zh) | 一种蜂蜜饮料 | |
JP6025538B2 (ja) | 分岐鎖アミノ酸の劣化臭抑制剤及び劣化臭抑制方法 | |
JP2021090412A (ja) | 不快味マスキング剤、酸性タンパク質飲料、不快味マスキング方法、及び酸性タンパク質飲料の製造方法 | |
JP6498830B1 (ja) | カカオ豆加工物含有飲料 | |
JP2022081425A (ja) | 鉄化合物含有組成物 | |
JP2022151696A (ja) | 鉄化合物およびコラーゲン含有飲料 | |
JP2022151697A (ja) | 鉄化合物およびセラミド含有飲料 | |
US20120178673A1 (en) | Fat accumulation suppressor | |
JPH11243914A (ja) | カルシウム吸収促進飲食物 | |
JPH05207865A (ja) | 天然のビタミンcを高単位に含有してなる栄養補給食品 | |
KR102237526B1 (ko) | 오르니틴 생성능이 우수한 락토바실러스 브레비스 wikim47를 이용한 마늘 발효 조성물 | |
JP2013538822A (ja) | 三価クロム・ホウ素強化組成物、栄養補助水、及びその調製方法 | |
JP2016039803A (ja) | 亜鉛・銅強化組成物、栄養補助水、及びその調製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2021576325 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21894547 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21894547 Country of ref document: EP Kind code of ref document: A1 |